Shanghai Junshi Biosciences Co., Ltd. Class H (HK:1877)
:1877
Want to see HK:1877 full AI Analyst Report?
1877 Stock Chart & Stats
HK$27.54
-HK$0.08(-0.74%)
At close: 4:00 PM EST
HK$27.54
-HK$0.08(-0.74%)
Day’s Range― - ―
52-Week RangeHK$15.66 - HK$38.64
Previous CloseN/A
Volume306.00K
Average Volume (3M)7.63M
Market Cap
HK$38.76B
Enterprise ValueHK$39.88B
Total Cash (Recent Filing)HK$4.55B
Total Debt (Recent Filing)HK$5.96B
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding260,295,700
10 Day Avg. Volume5,398,960
30 Day Avg. Volume7,633,399
Financial Highlights & Ratios
PEG Ratio0.64
Price to Book (P/B)3.19
Price to Sales (P/S)7.92
P/FCF Ratio-15.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$32.17Price Target Upside16.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.44
Revenue Forecast (FY)HK$3.31B
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~78.7% gross margins indicate strong product-level economics typical of biologics. High margins provide durable capacity to fund R&D and commercial scale-up once operating leverage improves, supporting long-term profitability potential even before full EBITDA breakeven.
Revenue Growth / Commercial TractionConsistent top-line growth (TTM +8.8%, stronger metric in fundamentals) shows the company is gaining commercial traction for approved products. Steady revenue expansion over multiple periods supports durable market adoption and provides a foundation to leverage fixed costs and improve margins over 2–6 months.
Integrated R&D-to-commercial ModelOperating across discovery, clinical development, manufacturing and commercialization creates vertical integration advantages: better control of supply, faster handoffs from R&D to market, and multiple monetization paths (sales, licensing), which supports resilient business fundamentals and diversified revenue sources.
Bears Say
Persistent Net LossesThe company remains meaningfully unprofitable with roughly -35% net margin. Persistent losses erode equity and require continued operating improvements or funding; until structural profitability is achieved, shareholder value is at risk if operating leverage or pricing dynamics don’t improve.
Negative Operating And Free Cash FlowSignificant negative operating and free cash flow indicate the business is burning cash and likely reliant on external financing. Continued cash consumption constrains investment flexibility, raises dilution/refinancing risk, and makes long-term project funding or large launches contingent on capital access.
Rising Leverage And Negative ROELeverage has increased to a moderate level (D/E ~0.69) while returns on equity are negative (~-14%). Higher debt combined with negative ROE reduces financial flexibility, increases interest and refinancing risk, and signals the company is not yet generating returns above its cost of capital.
Shanghai Junshi Biosciences Co., Ltd. Class H News
1877 FAQ
What was Shanghai Junshi Biosciences Co., Ltd. Class H’s price range in the past 12 months?
Shanghai Junshi Biosciences Co., Ltd. Class H lowest stock price was HK$15.66 and its highest was HK$38.64 in the past 12 months.
What is Shanghai Junshi Biosciences Co., Ltd. Class H’s market cap?
Shanghai Junshi Biosciences Co., Ltd. Class H’s market cap is HK$38.76B.
When is Shanghai Junshi Biosciences Co., Ltd. Class H’s upcoming earnings report date?
Shanghai Junshi Biosciences Co., Ltd. Class H’s upcoming earnings report date is Aug 27, 2026 which is in 94 days.
How were Shanghai Junshi Biosciences Co., Ltd. Class H’s earnings last quarter?
Shanghai Junshi Biosciences Co., Ltd. Class H released its earnings results on Apr 27, 2026. The company reported -HK$0.023 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.023.
Is Shanghai Junshi Biosciences Co., Ltd. Class H overvalued?
According to Wall Street analysts Shanghai Junshi Biosciences Co., Ltd. Class H’s price is currently Undervalued.
Does Shanghai Junshi Biosciences Co., Ltd. Class H pay dividends?
Shanghai Junshi Biosciences Co., Ltd. Class H does not currently pay dividends.
What is Shanghai Junshi Biosciences Co., Ltd. Class H’s EPS estimate?
Shanghai Junshi Biosciences Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai Junshi Biosciences Co., Ltd. Class H have?
Shanghai Junshi Biosciences Co., Ltd. Class H has 260,295,700 shares outstanding.
What happened to Shanghai Junshi Biosciences Co., Ltd. Class H’s price movement after its last earnings report?
Shanghai Junshi Biosciences Co., Ltd. Class H reported an EPS of -HK$0.023 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.773%.
Which hedge fund is a major shareholder of Shanghai Junshi Biosciences Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:1877
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Junshi Biosciences Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$32.17 (16.80% Upside)
HK$32.17 (16.80% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
95.67%
12-Months-Change
Fundamentals
Return on Equity
-10.78%
Trailing 12-Months
Asset Growth
37.38%
Trailing 12-Months
Company Description
Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
1877 Stock 12 Month Forecast
Average Price Target
HK$32.17
▲(16.80% Upside)
Technical Analysis
Innovent Biologics
―
Zai Lab Ltd
―
Akeso, Inc.
―
RemeGen Co. Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―
Options Prices
Currently, No data available
---